Deep Track Biotechnology Master Fund, Ltd. - 10 Feb 2026 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Reporting relationship: 10%+ Owner
Issuer ticker: DVAX
Reported as of: 10 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Feb 2026, 16:30:23 UTC
Prior SEC filing: 10 Feb 2026
Next SEC filing: 03 Aug 2026
Source filing: View source filing
Reporting owner signature: Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director

Key filing fact

Deep Track Biotechnology Master Fund, Ltd. filed Form 4 for DYNAVAX TECHNOLOGIES CORP (DVAX) on 11 Feb 2026.

Key facts

This page summarizes Deep Track Biotechnology Master Fund, Ltd.'s Form 4 filing for DYNAVAX TECHNOLOGIES CORP (DVAX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Feb 2026, 16:30.

Change

Previous filing in this sequence was filed on 10 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0002015536 Primary reporting owner

Deep Track Biotechnology Master Fund, Ltd.

Relationship: 10%+ Owner
Address: C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVE, GEORGE TOWN, CAYMAN ISLANDS
Signature: Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director
Signature date: 11 Feb 2026

CIK 0001856083

Deep Track Capital, LP

Relationship: 10%+ Owner
Address: 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH
Signature: Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser
Signature date: 11 Feb 2026

CIK 0001397513

KROIN DAVID

Relationship: 10%+ Owner
Address: C/O DEEP TRACK CAPITAL, LP,, 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH
Signature: /s/ David Kroin
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DVAX transaction

Common Stock, par value $0.001 per share

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -15,726,349
Change %: -100%
Price
Shares after: 0
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Deep Track Biotechnology Master Fund, Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Persons were tendered in exchange for the Offer Price.

Footnote F2

Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.